Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.42 |
| ▸ | JAK2 | O60674 | 11/20 | 0.42 |
| ▸ | AURKA | O14965 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | FLT3 | P36888 | 4/20 | 0.42 |
| ▸ | TYK2 | P29597 | 7/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 7/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.39 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406662 | 0.97 | ALOX5AP (0.41) | JAK1JAK2AURKAKDRFLT3 | |
| SCHEMBL25523073 | 0.97 | ALOX5AP (0.41) | JAK1JAK2AURKAKDRFLT3 | |
| SCHEMBL3134178 | 0.87 | JAK2 (0.40) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL31251321 | 0.80 | FAAH (0.36) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL4062743 | 0.74 | AXL (0.32) | — | |
| SCHEMBL28298844 | 0.73 | AXL (0.33) | JAK1JAK2 | |
| SCHEMBL6946172 | 0.72 | PAK1 (0.35) | JAK1JAK2AURKAKDRFLT3 | |
| SCHEMBL16113191 | 0.72 | APP (0.32) | — | |
| Hydrochloric Acid SCHEMBL6821627 | 0.71 | PAK1 (0.34) | JAK1JAK2AURKAKDRFLT3 | |
| SCHEMBL10600434 | 0.71 | PAK1 (0.37) | JAK1JAK2AURKAKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | CCNA1, CCNT1, TP53 | JAK1 341/4885JAK2 280/4885AURKA 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.